跳至主要内容
临床试验/NCT03149939
NCT03149939已完成不适用

Use of Febuxostat in Hyperuricemia Among Hemodialysis Patients

Benha University0 个研究点目标入组 19 人开始时间: 2017年1月1日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
19
主要终点
Change in serum uric acid

研究概览

简要总结

Hyperuricemia is not infrequently encountered among hemodialysis patients. However, there is no clear data about use of febuxostat among hemodialysis patients, apart from very small case series. The aim of this study is to investigate the efficacy of using febuxostat for the treatment of Hyperuricemia among hemodialysis patients.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age above 18 years
  • Hemodialysis patient
  • Hyperuricemia (Uric acid level above 6.0 mg/dL in females and 7.0 mg/dL in males)

排除标准

  • Patient currently and/or recently received drugs for hyperuricemia within the last three months
  • Patient had recent (within 3 months) change of erythropoiesis stimulating drugs or other drug known to increase uric acid e.g furosemide

结局指标

主要结局

Change in serum uric acid

时间窗: at three months of Febuxostat 40 milligrams Tablet therapy

Change in serum uric acid after 3 months of Febuxostat 40 milligrams Tablet therapy

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mahmoud Hamada imam

MD. - Lecturer at Internal Medicine Department- Faculty of Medicine

Benha University

相似试验

Use of Febuxostat in Hyperuricemia Among... | 临床试验